Watermark
  Back to Search Results

AdvanTIG-302

Terminated

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

AdvanTIG-302

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT04746924

EudraCT or EUCT Number Info icon SVG graphic used for tooltips or additional information.

2023

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20211476/CTR20211464

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Plain Language Summary Study Protocol Statistical Analysis Plan

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Plain Language Summary Study Protocol Statistical Analysis Plan